Overview

* Ocugen ( OCGN ) Q3 revenue beats analyst expectations, reaching $1.75 mln

* Company closed $20 mln direct offering, extending cash runway into 2026

* Executed licensing agreement with Kwangdong for OCU400 rights in South Korea

Outlook

* Ocugen ( OCGN ) plans BLA filing for OCU410ST in 1H 2027

* Company expects interim data for OCU410ST mid-2026

* Ocugen's ( OCGN ) cash runway extended into 2027 with warrant exercise

Result Drivers

* Total operating expenses for the three months ended September 30, 2025 were $19.4 million and included research and development expenses of $11.2 million and general and administrative expenses of $8.2 million

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.75 $550,000

Revenue mln (4

Analysts

)

Q3 Net -$20.05

Income mln

Q3 $19.37

Operatin mln

g

Expenses

Q3 -$17.62

Profit mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Ocugen Inc ( OCGN ) is $7.00, about 79.6% above its November 4 closing price of $1.43

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)